Foundation Medicine and Guardant Health Agree to Settle Patent Infringement Lawsuit
18 Julio 2018 - 3:00PM
Business Wire
Foundation Medicine, Inc. (NASDAQ:FMI) and Guardant Health, Inc.
announced an agreement to settle a patent infringement lawsuit
brought by Foundation Medicine against Guardant concerning U.S.
Patent No. 9,340,830. Under the terms of the settlement, the
lawsuit and counterclaims, as well as challenges to the patent in
inter partes review, have been dismissed. Financial terms and other
specifics of the settlement were not disclosed.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20180718005773/en/
About Foundation MedicineFoundation Medicine (NASDAQ:FMI)
is a molecular information company dedicated to a transformation in
cancer care in which treatment is informed by a deep understanding
of the genomic changes that contribute to each patient's unique
cancer. The company offers a full suite of comprehensive genomic
profiling assays to identify the molecular alterations in a
patient's cancer and match them with relevant targeted therapies,
immunotherapies and clinical trials. Foundation Medicine’s
molecular information platform aims to improve day-to-day care for
patients by serving the needs of clinicians, academic researchers
and drug developers to help advance the science of molecular
medicine in cancer. For more information, please visit
www.FoundationMedicine.com or follow Foundation Medicine on Twitter
(@FoundationATCG).
About Guardant Health, Inc.Guardant Health is a leading
precision oncology company focused on helping conquer cancer
globally through use of its proprietary blood tests, vast data sets
and advanced analytics. Its Guardant Health Oncology Platform is
designed to leverage its capabilities in technology, clinical
development, regulatory and reimbursement to drive commercial
adoption, improve patient clinical outcomes and lower healthcare
costs. In pursuit of its goal to manage cancer across all stages of
the disease, Guardant Health has launched multiple liquid
biopsy-based tests, Guardant360 and GuardantOMNI, for advanced
stage cancer patients, which fuel its development programs for
recurrence and early detection, LUNAR-1 and LUNAR-2, respectively.
Since its launch in 2014, Guardant360 has become the world's
market-leading comprehensive liquid biopsy test and has been used
by more than 5,000 oncologists, over 40 biopharmaceutical companies
and all 27 of the National Comprehensive Cancer Network Centers.
Learn more at www.guardanthealth.com.
Foundation Medicine® is a registered trademark of Foundation
Medicine, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180718005773/en/
For Foundation Medicine:Media Contact:Lee-Ann
Murphy, 617-245-3077pr@foundationmedicine.comorInvestor
Contact:Kimberly Brown,
617-418-2215ir@foundationmedicine.comorFor Guardant
Health:Media Contact:press@guardanthealth.com
Foundation Medicine, Inc. (NASDAQ:FMI)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Foundation Medicine, Inc. (NASDAQ:FMI)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
